Dr. Yetik-Anacak (PhD, B. pharm) is an associate professor in Pharmacology at Ege University, Faculty of Pharmacy, Department of Pharmacology, Turkey, since 2010. She had received the PhD degree in Pharmacology from Ege University (2002) by thesis studies on endothelial pharmacology performed at Research Institute of Genetic Engineering and Biotechnology of TUBITAK. She started to investigate the role of hsp90 in regulation of sGC in vasculature during her postdoctoral studies at Vascular Biology Center of Medical College of Georgia, USA for 2 years. Later she was studied on angiogenesis in Medical University of Wien, Vascular Biology Center. She has been investigating signaling pathways and treatments in erectile function and dysfunction. Her last studies focused on finding H2S-targeted drug candidates to treat erectile dysfunction, which is accepted as a marker for cardiovascular health. She was studied also on developing a biosensor to measure eNOS activity. She got a young investigator award from Turkish Academia and several grants from Turkish scientific consulate. Recently she started to investigate drug candidates targeting hydrogen sulfide (H2S). She has national and international collaboration with several laboratories and enrolled as management committee (MC) member of COST action BM1005; European network of gasotransmitters (ENOG) and COST action CA15135; Multitaget paradigm for innovative ligand identification in the drug discovery process (MuTaLig). She is also interested with age-related diseases, the management of pharmacological treatment of aging-induced diseases and member of age mouse networking group in COST action BM1402, (MouseAge). Her work is dedicated to elucidate the roles of gasotransmitters (especially nitric oxide and hydrogen sulfide) on vascular pharmacology, urogenital pharmacology and prostate cancer. She was studied also on developing a biosensor to measure eNOS activity.
Vascular tonus; Identifying H2S targeted drugs candidates; targets and treatments for aging-induced diseases.